Cargando…
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
This is a Brighton Collaboration Case Definition of the term “Vaccine Associated Enhanced Disease” to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI)...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901381/ https://www.ncbi.nlm.nih.gov/pubmed/33637387 http://dx.doi.org/10.1016/j.vaccine.2021.01.055 |
_version_ | 1783654377515384832 |
---|---|
author | Munoz, Flor M. Cramer, Jakob P. Dekker, Cornelia L. Dudley, Matthew Z. Graham, Barney S. Gurwith, Marc Law, Barbara Perlman, Stanley Polack, Fernando P. Spergel, Jonathan M. Van Braeckel, Eva Ward, Brian J. Didierlaurent, Arnaud M. Lambert, Paul Henri |
author_facet | Munoz, Flor M. Cramer, Jakob P. Dekker, Cornelia L. Dudley, Matthew Z. Graham, Barney S. Gurwith, Marc Law, Barbara Perlman, Stanley Polack, Fernando P. Spergel, Jonathan M. Van Braeckel, Eva Ward, Brian J. Didierlaurent, Arnaud M. Lambert, Paul Henri |
author_sort | Munoz, Flor M. |
collection | PubMed |
description | This is a Brighton Collaboration Case Definition of the term “Vaccine Associated Enhanced Disease” to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission. |
format | Online Article Text |
id | pubmed-7901381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79013812021-02-24 Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data Munoz, Flor M. Cramer, Jakob P. Dekker, Cornelia L. Dudley, Matthew Z. Graham, Barney S. Gurwith, Marc Law, Barbara Perlman, Stanley Polack, Fernando P. Spergel, Jonathan M. Van Braeckel, Eva Ward, Brian J. Didierlaurent, Arnaud M. Lambert, Paul Henri Vaccine Review This is a Brighton Collaboration Case Definition of the term “Vaccine Associated Enhanced Disease” to be utilized in the evaluation of adverse events following immunization. The Case Definition was developed by a group of experts convened by the Coalition for Epidemic Preparedness Innovations (CEPI) in the context of active development of vaccines for SARS-CoV-2 vaccines and other emerging pathogens. The case definition format of the Brighton Collaboration was followed to develop a consensus definition and defined levels of certainty, after an exhaustive review of the literature and expert consultation. The document underwent peer review by the Brighton Collaboration Network and by selected Expert Reviewers prior to submission. The Author(s). Published by Elsevier Ltd. 2021-05-21 2021-02-23 /pmc/articles/PMC7901381/ /pubmed/33637387 http://dx.doi.org/10.1016/j.vaccine.2021.01.055 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Munoz, Flor M. Cramer, Jakob P. Dekker, Cornelia L. Dudley, Matthew Z. Graham, Barney S. Gurwith, Marc Law, Barbara Perlman, Stanley Polack, Fernando P. Spergel, Jonathan M. Van Braeckel, Eva Ward, Brian J. Didierlaurent, Arnaud M. Lambert, Paul Henri Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data |
title | Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data |
title_full | Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data |
title_fullStr | Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data |
title_full_unstemmed | Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data |
title_short | Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data |
title_sort | vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7901381/ https://www.ncbi.nlm.nih.gov/pubmed/33637387 http://dx.doi.org/10.1016/j.vaccine.2021.01.055 |
work_keys_str_mv | AT munozflorm vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT cramerjakobp vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT dekkercornelial vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT dudleymatthewz vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT grahambarneys vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT gurwithmarc vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT lawbarbara vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT perlmanstanley vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT polackfernandop vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT spergeljonathanm vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT vanbraeckeleva vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT wardbrianj vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT didierlaurentarnaudm vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT lambertpaulhenri vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata AT vaccineassociatedenhanceddiseasecasedefinitionandguidelinesfordatacollectionanalysisandpresentationofimmunizationsafetydata |